Adage Capital Management focuses on managing S&a;P 500 assets predominantly for endowments and foundations.
Business Model:
Revenue: $3.7M
Employees: 11-50
Address: 200 Clarendon Street
City: Boston
State: MA
Zip: 02116
Country: US
Adage Capital Management is a Boston-based $8.9B Money Management firm focused on managing S&a;P 500 assets predominantly for Endowments and Foundations such as Harvard University, Northwestern University, Dartmouth College, the American Red Cross and the Getty Foundation. Adage and its predecessor, the Select Equity Group at the Harvard Management Company, has outperformed the S&a;P index in each of the last 15 years by an average of 3.5%. The fund is run by Phill Gross, who prior to founding Adage, was a Healthcare and Retail analyst, equity research director and partner at the Harvard Management Company for 18 years..
Contact Phone:
+16178672800
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
3/2018 | Prevail Therapeutics | Series A | 75M |
11/2020 | MedAvail | Series E | 0 |
1/2021 | Werewolf Therapeutics | Series B | 0 |
7/2022 | Annexon Biosciences | Post-IPO Equity | 0 |
10/2021 | Pyramid Biosciences | Series B | 0 |
11/2018 | Cabaletta Bio | Series A | 38M |
4/2014 | Epirus Biopharmaceuticals | Series B | 36M |
12/2012 | Ultragenyx Pharmaceutical | Series B | 75M |
10/2018 | Tanium | Private Equity Round | 200M |
4/2017 | SteadyMed Therapeutics | Post-IPO Equity | 0 |
4/2021 | Arcellx | Series C | - |
6/2020 | C4 Therapeutics | Series B | 150M |
10/2013 | Calithera Biosciences | Series D | 35M |
10/2011 | Puma Biotechnology | Post-IPO Equity | 55M |
2/2022 | Energy Vault | Post-IPO Equity | 150M |
5/2021 | SiMa.ai | Series B | 80M |
10/2021 | Scout Bio | Series B | 0 |
9/2019 | GitLab | Series E | 268M |
2/2021 | HemoShear Therapeutics | Series A | 40M |
9/2017 | Engage Therapeutics | Series A | 23.6M |
4/2014 | Vapotherm | Series B | 0 |
4/2021 | Arch Oncology | Series C | 0 |
7/2021 | Gopuff | Series H | 0 |
8/2020 | Pyramid Biosciences | Venture Round | 0 |
4/2021 | HawkEye 360 | Series C | 0 |
12/2022 | Karyopharm Therapeutics | Post-IPO Equity | 0 |
12/2017 | Aptinyx | Series B | 70M |
5/2020 | Amplyx Pharmaceuticals | Series C | 0 |
5/2020 | Pulmonx | Equity | 66M |
5/2021 | Larimar Therapeutics | Post-IPO Equity | 0 |
6/2018 | Precision BioSciences | Series B | 0 |
4/2021 | Antios Therapeutics | Series B | 0 |
4/2014 | Nexvet | Series B | 31.5M |
3/2019 | Scout Bio | Series B | 20M |
6/2020 | Poseida Therapeutics | Series D | 110M |
4/2021 | Stem | Post-IPO Equity | 225M |
7/2020 | Cerevel Therapeutics | Post-IPO Equity | 0 |
2/2020 | Flywire | Series E | 120M |
9/2022 | Ventyx Biosciences | Post-IPO Equity | 0 |
3/2014 | Lumena Pharmaceuticals | Series B | 45M |
12/2015 | Welldoc | Series B | 0 |
9/2018 | Galera Therapeutics | Series C | 70M |
2/2021 | Silence Therapeutics | Post-IPO Equity | 0 |
1/2019 | Cabaletta Bio | Series B | 0 |
8/2021 | Pepgen | Venture Round | 0 |
11/2020 | Ambrx | Private Equity Round | 200M |
6/2021 | ImaginAb | Growth | 12.8M |
6/2015 | Advanced Accelerator Applications | Venture Round | 25.7M |
2/2005 | FibroGen | Venture Round | 0 |
10/2014 | MedAvail | Series C | 0 |
7/2018 | MedAvail | Series D | 0 |
5/2021 | PathAI | Series C | 0 |
3/2013 | PTC Therapeutics | Private Equity Round | 60M |
3/2021 | Flywire | Series F | 60M |
3/2015 | Aimmune Therapeutics | Series B | 80M |
9/2015 | AveXis | Series D | 65M |
11/2015 | Vapotherm | Series C | 0 |
4/2022 | Harness | Series D | 0 |
12/2018 | Annexon Biosciences | Series C | 75M |
3/2019 | Prevail Therapeutics | Series B | 50M |
3/2022 | Menlo Micro | Series C | 0 |
11/2021 | Antios Therapeutics | Series B | 0 |
3/2015 | Collegium Pharmaceutical | Private Equity Round | 0 |
5/2021 | Forter | Series F | 300M |
6/2021 | Goat Group | Series F | 195M |
3/2021 | Aura Biosciences | Venture Round | 0 |
7/2008 | Portola Pharmaceuticals | Series C | 60.1M |
4/2008 | Concert Pharmaceuticals | Series C | 0 |
7/2015 | Protagonist Therapeutics | Series C | 0 |
11/2021 | HawkEye 360 | Series D | 0 |
7/2020 | Praxis Precision Medicines | Series C | 0 |
3/2021 | Caribou Biosciences | Series C | 115M |
7/2015 | Vapotherm | Series C | 0 |
3/2014 | ZS Pharma | Series D | 0 |
8/2021 | Beckley Psytech | Series B | 0 |
11/2015 | AppDynamics | Series F | 0 |
10/2021 | CinCor Pharma | Series B | 0 |
9/2020 | Eledon Pharmaceuticals | Post-IPO Equity | 108M |
2/2015 | Advaxis | Post-IPO Equity | 0 |
12/2021 | connectRN | Venture Round | 0 |
11/2022 | BioAtla | Post-IPO Equity | 0 |
4/2014 | Adverum Biotechnologies | Series B | 55M |
11/2022 | Abeona Therapeutics | Post-IPO Equity | 0 |
9/2017 | ImaginAb | Venture Round | 0 |
4/2021 | Theseus Pharmaceuticals | Series B | 0 |
3/2021 | Rapid Micro Biosystems | Private Equity Round | 0 |
7/2020 | Annexon Biosciences | Series C | 100M |
9/2020 | Flame Biosciences | Venture Round | 100M |
7/2022 | Annexon Biosciences | Post-IPO Equity | 0 |
4/2022 | Harness | Series D | 0 |
3/2022 | Menlo Micro | Series C | 0 |
2/2022 | Energy Vault | Post-IPO Equity | 0 |
12/2021 | connectRN | Venture Round | 0 |
11/2021 | HawkEye 360 | Series D | 0 |
11/2021 | Antios Therapeutics | Series B | 0 |
10/2021 | Scout Bio | Series B | 0 |
10/2021 | Pyramid Biosciences | Series B | 0 |
10/2021 | CinCor Pharma | Series B | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|